BCTX vs. PMN, VYNE, IPA, FBIO, CARA, JAN, UNCY, MRKR, ELDN, and CLNN
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include ProMIS Neurosciences (PMN), VYNE Therapeutics (VYNE), ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), Cara Therapeutics (CARA), JanOne (JAN), Unicycive Therapeutics (UNCY), Marker Therapeutics (MRKR), Eledon Pharmaceuticals (ELDN), and Clene (CLNN). These companies are all part of the "pharmaceutical preparations" industry.
BriaCell Therapeutics (NASDAQ:BCTX) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
BriaCell Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 710.81%. ProMIS Neurosciences has a consensus price target of $8.00, suggesting a potential upside of 308.16%. Given BriaCell Therapeutics' higher probable upside, equities analysts clearly believe BriaCell Therapeutics is more favorable than ProMIS Neurosciences.
ProMIS Neurosciences has higher revenue and earnings than BriaCell Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
BriaCell Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
In the previous week, BriaCell Therapeutics had 1 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 1 mentions for BriaCell Therapeutics and 0 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 0.80 beat BriaCell Therapeutics' score of 0.00 indicating that ProMIS Neurosciences is being referred to more favorably in the news media.
15.4% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are owned by institutional investors. 21.8% of BriaCell Therapeutics shares are owned by insiders. Comparatively, 10.3% of ProMIS Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
BriaCell Therapeutics received 2 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users.
Summary
BriaCell Therapeutics beats ProMIS Neurosciences on 7 of the 13 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
